Clinical Practice Liaison, Northern California
Madrigal Pharmaceuticals
Summary
The Clinical Practice Liaison (CPL) plays a vital field-based role within Madrigal's Medical Affairs team, focused on improving the standard of care for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). The CPL will proactively engage healthcare professionals (HCPs) to provide guideline-based, non-promotional disease education on the identification, diagnosis, and management of MASH. This role centers on empowering clinical practices to adopt evidence-based care pathways, integrate non-invasive diagnostic tools, enhance risk stratification, and collaborate in multidisciplinary care models. The CPL will also serve as a bridge between the medical community and internal Madrigal teams, providing strategic insights that help shape broader corporate understanding and direction.
Job description
Key Responsibilities and Primary Activities
Scientific & Clinical Education
- Deliver unbiased, evidence-based education on MASH to HCPs based on identified gaps in knowledge or clinical implementation
- Present current clinical practice guidelines and real-world data on diagnosis, risk stratification, and patient management
- Maintain deep understanding of Non-Invasive Testing (NITs), treatment paradigms, and clinical protocols across the liver/metabolic spectrum
Practice Engagement & Enablement
- Engage with clinicians, practice managers, and office staff to support implementation of MASH care protocols
- Support the integration of guideline-based approaches into routine clinical workflows and align practices with payer and quality standards
- Respond to unsolicited clinical and drug-related inquiries in a scientifically accurate and compliant manner
Cross-Functional Collaboration
- Partner with internal Medical Affairs and Commercial colleagues to address clinical questions and ensure consistent field insights
- Contribute scientific expertise to speaker training programs, advisory boards, and internal stakeholder education
- Represent Madrigal at national and regional scientific meetings, supporting booth activities and engaging in peer-to-peer exchange
Insight Gathering & Strategic Feedback
- Capture and report actionable insights from clinical practices to inform corporate strategies and educational content development
- Monitor evolving clinical trends and barriers to care in MASH to support internal planning and market awareness
Compliance & Professional Standards
- Adhere strictly to all applicable company and regulatory policies, including FDA and industry guidelines for non-promotional medical engagements
- Ensure thorough documentation and accountability for all scientific interactions
- Maintain a strong understanding of US regulations and compliance
Travel Requirement
Ability to travel up to 70% including support of scientific meetings over weekends.
Requirements
- Advanced healthcare or life science degree (e.g., PA, NP, PharmD, or other clinically relevant background)
- Clinical familiarity with MASH diagnostic tools, especially non-invasive testing and risk stratification methods
- Strong grasp of U.S. healthcare system operations, including practice workflows, billing/coding, and payer dynamics
- Excellent verbal and written communication skills; ability to distill complex science for various audiences
- Proficiency in Microsoft Office Suite, virtual communication platforms (e.g., Zoom, Teams), and related Medical Affairs Systems (e.g. Veeva Vault, CRM tools)
- Strong understanding of US regulations and compliance
- Ability to travel up to 70% including support of scientific meetings over weekends
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- 401(k) Matching
- Equity
- Flexible Paid Time Off
- Mental Health Benefits
- Employee Assistance Program
- Supplemental Life Insurance
- Legal Services
Company overview
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The company's lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor (THR)-β selective agonist that targets key underlying causes of MASH in the liver. Rezdiffra received FDA approval in 2024 as the first treatment for MASH with moderate to advanced liver fibrosis, representing a significant breakthrough in hepatology. Headquartered in Conshohocken, Pennsylvania, Madrigal is publicly traded on NASDAQ under the symbol MDGL. The company continues to advance its clinical development programs, including ongoing Phase 3 trials evaluating Rezdiffra for the treatment of compensated MASH cirrhosis. Madrigal's innovative approach addresses a critical unmet medical need in liver disease therapeutics.